Target intelligence / Profile preview

Influenza A hemagglutinin head domain (HA head domain)

Target
HA head domain
Molecular classification
Viral glycoprotein, Receptor-binding protein, Class I viral fusion protein (head domain), Other
01

Overview

The **Influenza A hemagglutinin head domain** is the globular, receptor-binding portion of the trimeric hemagglutinin (HA) glycoprotein located on the surface of influenza A viruses. The head domain is responsible for binding to sialic acid receptors on the surface of host cells, thereby mediating initial virus attachment and entry. It is also the main target for neutralizing antibodies, making it the critical antigenic region for protective immune responses and seasonal flu vaccine design. The HA head domain evolves rapidly, facilitating immune escape (antigenic drift), which necessitates frequent updates to influenza vaccine formulations. Broadly neutralizing antibodies targeting conserved regions of the head domain have been identified, but most neutralizing activity is directed at variable sites, limiting cross-strain protection. The head domain’s structure and antigenicity play a major role in the infectiousness, immunity, and epidemiological dynamics of influenza A virus.

Other names
Hemagglutinin globular head domainHA-RBD (receptor-binding domain)HA headInfluenza A virus hemagglutinin head
02

Mechanism of action

Blockade of receptor binding (neutralizing antibodies attach to the head domain and prevent viral entry); Inhibition of membrane fusion (via antibodies targeting conformational epitopes); Immune system mediated clearance (antibodies facilitate neutralization and clearance by immune cells)

03

Biological functions

Virus attachment to host cellHost receptor binding (sialic acid recognition)Major antigenic region for neutralizing antibodiesImmune system evasion (antigenic drift)
04

Disease associations

InfectionImmunity (major vaccine antigen)Pandemics, outbreaks (due to antigenic variability)
05

Safety considerations

High antigenic variability (rapid mutation can lead to immune escape and reduced vaccine efficacy)Vaccine mismatch risk (due to rapid antigenic drift in the head domain)Antibody-dependent enhancement (not generally noted for influenza, but theoretical risk with non-neutralizing antibodies)
06

Interacting drugs

Monoclonal antibodies (e.g., L4A-14, H7.5, H7-200)

2 more in the full profile.

07

Biomarkers

HA-specific antibodies (measured in hemagglutination-inhibition assays for vaccine efficacy or serology)Sequence variants of HA head domain (for influenza virus surveillance and vaccine design)

Beyond the preview

Go deeper on Influenza A hemagglutinin head domain (HA head domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A hemagglutinin head domain (HA head domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call